Marquis Karine, Debigaré Richard, Lacasse Yves, LeBlanc Pierre, Jobin Jean, Carrier Guy, Maltais François
Centre de recherche, Hôpital Laval, Institut Universtaire de Cardiologie et de Pneumologie de L'Université Laval, Québec, Canada.
Am J Respir Crit Care Med. 2002 Sep 15;166(6):809-13. doi: 10.1164/rccm.2107031.
This study was undertaken to test the hypothesis that a reduction in midthigh muscle cross-sectional area obtained by CT scan (MTCSA(CT)) is a better predictor of mortality in chronic obstructive pulmonary disease (COPD) than low body mass index (BMI). We also wished to evaluate whether anthropometric measurements could be used to estimate MTCSA(CT). One hundred forty-two patients with COPD (age = 65 +/- 9 years, mean +/- SD, 26 F, BMI = 26 +/- 6 kg/m(2), FEV(1) = 42 +/- 16% predicted) were recruited from September 1995 to April 2000 with a mean follow-up of 41 +/- 18 months. The primary end-point was all-cause mortality during the study period. A Cox proportional hazards regression model was used to predict mortality using the following independent variables: age, sex, daily use of corticosteroid, FEV(1), DL(CO), BMI, thigh circumference, MTCSA(CT), peak exercise workrate, Pa(O2), and Pa(CO2). Only MTCSA(CT) and FEV(1) were found to be significant predictors of mortality (p = 0.0008 and p = 0.01, respectively). A second analysis was also performed with FEV(1) and MTCSA(CT) dichotomized. Patients were divided into four subgroups based on FEV(1) (< or >or= 50% predicted) and MTCSA(CT) (< or >or= 70 cm(2)). Compared with patients with an FEV(1) >or= 50% predicted and a MTCSA(CT) >or= 70 cm(2), those with an FEV(1) < 50% predicted and a MTCSA(CT) >or= 70 cm(2) had a mortality odds ratio of 3.37 (95% confidence interval, 0.41-28.00), whereas patients with an FEV(1) < 50% predicted and a MTCSA(CT) < 70 cm(2) had a mortality odds ratio of 13.16 (95% confidence interval, 1.74-99.20). MTCSA(CT) could not be estimated with sufficient accuracy from anthropometric measurements. In summary, we found in this cohort of patients with COPD that (1) MTCSA(CT) was a better predictor of mortality than BMI, and (2) MTCSA had a strong impact on mortality in patients with an FEV(1) < 50% predicted. These findings suggest that the assessment of body composition may be useful in the clinical evaluation of these patients.
通过CT扫描获得的大腿中部肌肉横截面积(MTCSA(CT))减少,相较于低体重指数(BMI),是慢性阻塞性肺疾病(COPD)患者死亡率的更好预测指标。我们还希望评估人体测量指标是否可用于估算MTCSA(CT)。1995年9月至2000年4月招募了142例COPD患者(年龄 = 65±9岁,均值±标准差,女性26例,BMI = 26±6 kg/m²,FEV₁ = 42±16%预计值),平均随访41±18个月。主要终点为研究期间的全因死亡率。采用Cox比例风险回归模型,使用以下自变量预测死亡率:年龄、性别、皮质类固醇的每日使用量、FEV₁、DL(CO)、BMI、大腿围、MTCSA(CT)、峰值运动功率、Pa(O₂)和Pa(CO₂)。仅发现MTCSA(CT)和FEV₁是死亡率的显著预测指标(分别为p = 0.0008和p = 0.01)。还对FEV₁和MTCSA(CT)进行了二分法的二次分析。根据FEV₁(<或≥50%预计值)和MTCSA(CT)(<或≥70 cm²)将患者分为四个亚组。与FEV₁≥50%预计值且MTCSA(CT)≥70 cm²的患者相比,FEV₁<50%预计值且MTCSA(CT)≥70 cm²的患者死亡比值比为3.37(95%置信区间,0.41 - 28.00),而FEV₁<50%预计值且MTCSA(CT)<70 cm²的患者死亡比值比为13.16(95%置信区间,1.74 - 99.20)。无法通过人体测量指标足够准确地估算MTCSA(CT)。总之,在这组COPD患者中我们发现:(1)MTCSA(CT)比BMI是更好的死亡率预测指标;(2)对于FEV₁<50%预计值的患者,MTCSA对死亡率有强烈影响。这些发现表明,身体成分评估可能对这些患者的临床评估有用。